As we enter election year in 2020, the pressure has never been higher on our industry to justify what we add to the cost of healthcare. Price control has become a bipartisan issue and across the wide-range of policy positions that are on the table in Fall 2020, one area is clear: the transition towards value-based care is inevitable eyeforpharma philadelphia
Compared to last decade, when we were rightly taken to task for bloated pipelines with costly ‘me-too’ treatments, the situation couldn’t be more different. We are on the verge of a new golden age for R&D. Personalized care is starting to deliver. Innovations in cell gene, Car-T and curative therapies offer transformative impact to patients. The problem is: they are also very expensive. Let’s get ahead of this crisis and come together to define a better way forward.
